

Syndecan Peptides And Polypeptides As Inhibitors Of Vegfr2 And Vla-4

View U.S. Patent No. 9,878,007 in PDF format.

WARF: P150222US02

Inventors: Alan Rapraeger, Oisun Jung

The Invention

Peptides derived from amino acid residues 210 to 240 of human syndecan 1 and methods of use of such peptides are described. These peptides can inhibit activation of $\alpha 4\beta 1$ integrin (also known as very late antigen-4, VLA-4), and can inhibit engagement of VLA-4 with vascular endothelial growth factor receptor-2 (VEGFR2), thereby preventing tumor cell growth and tissue invasion.

Additional Information

For More Information About the Inventors

• Alan Rapraeger

Related Intellectual Property

• View Divisional Patent in PDF format.

Tech Fields

• Therapeutics & Vaccines : Oncology

For current licensing status, please contact Andy DeTienne at adetienne@warf.org or 608-960-9857